At a glance
- Originator Eisai Co Ltd
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 10 Aug 1999 Discontinued-II for Asthma in Japan (PO)
- 14 Aug 1997 Profile reviewed
- 13 Feb 1995 Phase-II clinical trials for Asthma in Japan (PO)